Quantum BioPharma Receives BUY Rating with $45 Price Target from Kingswood Capital
TL;DR
Quantum BioPharma's BUY rating and $45 target offer investors potential gains from its Lucid-MS drug advancing through clinical trials toward 2029 launch.
Kingswood's $45 valuation for Quantum BioPharma is based on discounted cash flow analysis assuming successful Phase 2/3 trials from 2026-2028 and commercial launch in 2029.
Quantum BioPharma's treatments for neurodegenerative and alcohol misuse disorders could significantly improve patient lives and advance medical science for challenging conditions.
Quantum BioPharma's Lucid-MS compound shows promise in reversing myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received a significant endorsement from Kingswood Capital Partners, which initiated coverage with a BUY rating and a $45 price target. The independent analysis, led by Kingswood Senior Equity Analyst Karen Sterling, PhD, CFA, values the biopharmaceutical company based on discounted cash flow projections that assume successful Phase 2 and 3 trials of its lead candidate Lucid-MS between 2026 and 2028, followed by commercial launch in 2029.
The rating is particularly important for investors and the biotech industry as it represents an unpaid, independent assessment of Quantum BioPharma's potential. The company focuses on developing treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Its lead compound, Lucid-MS, is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis—in preclinical models.
Beyond its pharmaceutical developments, Quantum BioPharma maintains additional revenue streams through its ownership stake in Unbuzzd Wellness Inc., where it holds 20.11% ownership as of March 31, 2025, and receives royalty payments of 7% of sales from the unbuzzd(TM) product until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical applications.
The implications of this BUY rating extend beyond immediate investor interest. For patients suffering from neurodegenerative diseases like multiple sclerosis, successful development of Lucid-MS could represent a breakthrough treatment addressing the fundamental mechanism of the disease rather than just managing symptoms. The biopharmaceutical industry closely watches such independent analyst ratings as they often signal which companies have strong potential for bringing innovative treatments to market.
Quantum BioPharma's strategic investments through its subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property, provide additional financial stability. Investors can access the latest company updates through its newsroom at https://ibn.fm/QNTM. The full Kingswood Capital report and analysis provides valuable insight for those monitoring the evolving landscape of neurodegenerative disease treatments and investment opportunities in the biopharmaceutical sector.
Curated from InvestorBrandNetwork (IBN)
